New pill plus immunotherapy shows promise for liver cancer
Disease control
Not yet recruiting
This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned t…
Phase: PHASE3 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:20 UTC